Fundamental & clinical pharmacology · 2025
Tamsulosin Attenuates Cardiac Hypertrophy via Integrin-Linked Kinase: Possible Mechanisms.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Alonazi Asma S, Bin Dayel Anfal F, Alomer Hetoun A, Altalasi Sara H, Almutairi Nouf B, Alamin Maha A, Hasan Iman H, Alajmi Hana N, Alrajeh Haya M, Alkhader Lama F, Al-Damry Nouf T, Alayoubi Samha, Ali Hebatallah H, Sarawi Wedad S, Al-Ghibiwi Hanan K, Alshammari Tahani K, Alrasheed Nawal M, Alrasheed Nouf M
Аннотация
BACKGROUND: Cardiac hypertrophy often transits into heart failure. Angiogenesis significantly affects the pathogenesis of cardiac hypertrophy. Cytoplasmic integrin-linked kinase (ILK) regulates cardiac angiogenesis by stimulating vascular endothelial growth factor (VEGF). There is a lack of evidence that investigates the effect of α1A-adrenoceptor blockade on ILK-related angiogenesis. Thus, the current study aims to examine the effect of tamsulosin on ILK-related angiogenesis.
METHOD: Twenty-four Wistar rats were divided into four groups as follows: control receiving 0.9% NaCl; an isoproterenol (ISO)-treated (5 mg/kg/day); tamsulosin-treated (0.4 mg/kg/day); and tamsulosin + ISO-treated group. The cardiac injuries, angiogenic biomarkers, and target proteins expressions were assessed.
RESULTS: Tamsulosin significantly attenuated the cardiac hypertrophy index and biomarkers. Tamsulosin reversed histopathological changes in cardiac tissues and mediated significant modulation in VEGF, eNOS, ILK, p-PI3K, p-Akt, Flt-1, and PECAM-1 expressions.
CONCLUSION: The data indicate that targeting α1A adrenoceptors by inhibition offers a promising therapeutic approach for preventing cardiac hypertrophy via signal-transduction pathways, including ILK-related VEGF/eNOS/PI3K/Akt.
METHOD: Twenty-four Wistar rats were divided into four groups as follows: control receiving 0.9% NaCl; an isoproterenol (ISO)-treated (5 mg/kg/day); tamsulosin-treated (0.4 mg/kg/day); and tamsulosin + ISO-treated group. The cardiac injuries, angiogenic biomarkers, and target proteins expressions were assessed.
RESULTS: Tamsulosin significantly attenuated the cardiac hypertrophy index and biomarkers. Tamsulosin reversed histopathological changes in cardiac tissues and mediated significant modulation in VEGF, eNOS, ILK, p-PI3K, p-Akt, Flt-1, and PECAM-1 expressions.
CONCLUSION: The data indicate that targeting α1A adrenoceptors by inhibition offers a promising therapeutic approach for preventing cardiac hypertrophy via signal-transduction pathways, including ILK-related VEGF/eNOS/PI3K/Akt.